Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: Real-Life Efficacy and Safety Analysis of Korean Patients
Transarterial radioembolization (TARE) has become widely used in the treatment of HCC, one of the most common causes of cancer mortality worldwide. Here we investigated the long-term clinical outcomes of patients with hepatocellular carcinoma (HCC) treated with TARE in a multi-medical center in Kore...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-01-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/2/385 |
| _version_ | 1797495318171877376 |
|---|---|
| author | Sun Young Yim Ho Soo Chun Jae Seung Lee Ji-Hwan Lim Tae Hyung Kim Beom Kyung Kim Seung Up Kim Jun Yong Park Sang Hoon Ahn Gyoung Min Kim Jong Yun Won Yeon Seok Seo Yun Hwan Kim Soon Ho Um Do Young Kim |
| author_facet | Sun Young Yim Ho Soo Chun Jae Seung Lee Ji-Hwan Lim Tae Hyung Kim Beom Kyung Kim Seung Up Kim Jun Yong Park Sang Hoon Ahn Gyoung Min Kim Jong Yun Won Yeon Seok Seo Yun Hwan Kim Soon Ho Um Do Young Kim |
| author_sort | Sun Young Yim |
| collection | DOAJ |
| description | Transarterial radioembolization (TARE) has become widely used in the treatment of HCC, one of the most common causes of cancer mortality worldwide. Here we investigated the long-term clinical outcomes of patients with hepatocellular carcinoma (HCC) treated with TARE in a multi-medical center in Korea. A total of 149 patients treated with TARE from 2008–2014 were recruited. The pre-treatment HCC stage was classified according to the BCLC stage, of which C and D were defined as advanced HCC. Advanced HCC stage and Child–Turcotte–Pugh (CTP) score A were identified in 62 (42%) and 134 (90%) patients, respectively. Portal vein thrombosis (PVT) was identified in 58 patients (38.9%). The median time to progression (TTP) was 14 months, and the median overall survival (OS) and progression-free survival (PFS) were 18.6 and 8.9 months, respectively. The overall tumor response was 47%, and the disease control rate was 78%. OS and PFS differed significantly according to the presence of liver cirrhosis, extrahepatic metastasis, tumor response and curative treatment after TARE (all, <i>p</i> < 0.05). Multiple tumors and major PVT were other independent factors related to OS, while the des-gamma carboxy protein level predicted PFS (all, <i>p</i> < 0.05). Tumor size was an independent predictor of tumor response. TTP, OS and PFS all differed among BCLC stages. The serious adverse effect after TARE was clinically not significant. Therefore, TARE is safe and effective in treating early to advanced HCCs. |
| first_indexed | 2024-03-10T01:46:09Z |
| format | Article |
| id | doaj.art-58656438ca894fe89d8cdabd79702549 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T01:46:09Z |
| publishDate | 2022-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-58656438ca894fe89d8cdabd797025492023-11-23T13:14:05ZengMDPI AGCancers2072-66942022-01-0114238510.3390/cancers14020385Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: Real-Life Efficacy and Safety Analysis of Korean PatientsSun Young Yim0Ho Soo Chun1Jae Seung Lee2Ji-Hwan Lim3Tae Hyung Kim4Beom Kyung Kim5Seung Up Kim6Jun Yong Park7Sang Hoon Ahn8Gyoung Min Kim9Jong Yun Won10Yeon Seok Seo11Yun Hwan Kim12Soon Ho Um13Do Young Kim14Department of Internal Medicine, Korea University College of Medicine, Korea University Anam Hospital, Seoul 02841, KoreaEwha Womans Medical Center, Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul 03760, KoreaDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul 03722, KoreaDepartment of Internal Medicine, Korea University College of Medicine, Korea University Anam Hospital, Seoul 02841, KoreaDepartment of Internal Medicine, Korea University College of Medicine, Korea University Anam Hospital, Seoul 02841, KoreaDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul 03722, KoreaDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul 03722, KoreaDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul 03722, KoreaDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul 03722, KoreaDepartment of Radiology, Severance Hospital, Research Institute of Radiological Science, Yonsei University School of Medicine, Seoul 03722, KoreaDepartment of Radiology, Severance Hospital, Research Institute of Radiological Science, Yonsei University School of Medicine, Seoul 03722, KoreaDepartment of Internal Medicine, Korea University College of Medicine, Korea University Anam Hospital, Seoul 02841, KoreaDepartment of Radiology, Korea University Anam Hospital, Seoul 02841, KoreaDepartment of Internal Medicine, Korea University College of Medicine, Korea University Anam Hospital, Seoul 02841, KoreaDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul 03722, KoreaTransarterial radioembolization (TARE) has become widely used in the treatment of HCC, one of the most common causes of cancer mortality worldwide. Here we investigated the long-term clinical outcomes of patients with hepatocellular carcinoma (HCC) treated with TARE in a multi-medical center in Korea. A total of 149 patients treated with TARE from 2008–2014 were recruited. The pre-treatment HCC stage was classified according to the BCLC stage, of which C and D were defined as advanced HCC. Advanced HCC stage and Child–Turcotte–Pugh (CTP) score A were identified in 62 (42%) and 134 (90%) patients, respectively. Portal vein thrombosis (PVT) was identified in 58 patients (38.9%). The median time to progression (TTP) was 14 months, and the median overall survival (OS) and progression-free survival (PFS) were 18.6 and 8.9 months, respectively. The overall tumor response was 47%, and the disease control rate was 78%. OS and PFS differed significantly according to the presence of liver cirrhosis, extrahepatic metastasis, tumor response and curative treatment after TARE (all, <i>p</i> < 0.05). Multiple tumors and major PVT were other independent factors related to OS, while the des-gamma carboxy protein level predicted PFS (all, <i>p</i> < 0.05). Tumor size was an independent predictor of tumor response. TTP, OS and PFS all differed among BCLC stages. The serious adverse effect after TARE was clinically not significant. Therefore, TARE is safe and effective in treating early to advanced HCCs.https://www.mdpi.com/2072-6694/14/2/385hepatocellular carcinomaoverall survivalprogression-free survivalrisk factortransarterial chemoembolization |
| spellingShingle | Sun Young Yim Ho Soo Chun Jae Seung Lee Ji-Hwan Lim Tae Hyung Kim Beom Kyung Kim Seung Up Kim Jun Yong Park Sang Hoon Ahn Gyoung Min Kim Jong Yun Won Yeon Seok Seo Yun Hwan Kim Soon Ho Um Do Young Kim Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: Real-Life Efficacy and Safety Analysis of Korean Patients Cancers hepatocellular carcinoma overall survival progression-free survival risk factor transarterial chemoembolization |
| title | Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: Real-Life Efficacy and Safety Analysis of Korean Patients |
| title_full | Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: Real-Life Efficacy and Safety Analysis of Korean Patients |
| title_fullStr | Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: Real-Life Efficacy and Safety Analysis of Korean Patients |
| title_full_unstemmed | Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: Real-Life Efficacy and Safety Analysis of Korean Patients |
| title_short | Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: Real-Life Efficacy and Safety Analysis of Korean Patients |
| title_sort | transarterial radioembolization for unresectable hepatocellular carcinoma real life efficacy and safety analysis of korean patients |
| topic | hepatocellular carcinoma overall survival progression-free survival risk factor transarterial chemoembolization |
| url | https://www.mdpi.com/2072-6694/14/2/385 |
| work_keys_str_mv | AT sunyoungyim transarterialradioembolizationforunresectablehepatocellularcarcinomareallifeefficacyandsafetyanalysisofkoreanpatients AT hosoochun transarterialradioembolizationforunresectablehepatocellularcarcinomareallifeefficacyandsafetyanalysisofkoreanpatients AT jaeseunglee transarterialradioembolizationforunresectablehepatocellularcarcinomareallifeefficacyandsafetyanalysisofkoreanpatients AT jihwanlim transarterialradioembolizationforunresectablehepatocellularcarcinomareallifeefficacyandsafetyanalysisofkoreanpatients AT taehyungkim transarterialradioembolizationforunresectablehepatocellularcarcinomareallifeefficacyandsafetyanalysisofkoreanpatients AT beomkyungkim transarterialradioembolizationforunresectablehepatocellularcarcinomareallifeefficacyandsafetyanalysisofkoreanpatients AT seungupkim transarterialradioembolizationforunresectablehepatocellularcarcinomareallifeefficacyandsafetyanalysisofkoreanpatients AT junyongpark transarterialradioembolizationforunresectablehepatocellularcarcinomareallifeefficacyandsafetyanalysisofkoreanpatients AT sanghoonahn transarterialradioembolizationforunresectablehepatocellularcarcinomareallifeefficacyandsafetyanalysisofkoreanpatients AT gyoungminkim transarterialradioembolizationforunresectablehepatocellularcarcinomareallifeefficacyandsafetyanalysisofkoreanpatients AT jongyunwon transarterialradioembolizationforunresectablehepatocellularcarcinomareallifeefficacyandsafetyanalysisofkoreanpatients AT yeonseokseo transarterialradioembolizationforunresectablehepatocellularcarcinomareallifeefficacyandsafetyanalysisofkoreanpatients AT yunhwankim transarterialradioembolizationforunresectablehepatocellularcarcinomareallifeefficacyandsafetyanalysisofkoreanpatients AT soonhoum transarterialradioembolizationforunresectablehepatocellularcarcinomareallifeefficacyandsafetyanalysisofkoreanpatients AT doyoungkim transarterialradioembolizationforunresectablehepatocellularcarcinomareallifeefficacyandsafetyanalysisofkoreanpatients |